Table 2

Baseline characteristics by 30-day survival status

VariableSurvivors (n=136)Non-survivors (n=29)
Age (years), mean±SD58±1663±14
Gender (% female)59 (43)13 (45)
Race, n (%)
White116 (70)18 (62)
Non-white49 (30)11 (38)
Underlying malignancy, n (%)
Acute myelogenous leukaemia124 (91)25 (86)
Myelodysplastic syndrome9 (7)1 (3)
Acute lymphoblastic leukaemia3 (2)3 (10)
Intensive chemotherapy at induction, n (%)71 (52)13 (45)
ECOG, n (%)
 020 (15)3 (10)
 182 (60)15 (52)
 229 (21)9 (31)
 34 (3)2 (7)
 41 (1)0
Pneumonia at time of induction, n (%)26 (19)4 (14)
Laboratory data
 Haemoglobin (g/L)87±1680±17
 Platelet count (109 cells/L)59±5256±47
 Absolute neutrophil count (109 cells/L)2.0±4.83.4±8.0
 Total bilirubin (mg/dL)0.6±0.41.0±1.2
 Creatinine (mg/dL)1.1±0.71.0±0.4
 Positive blood culture, n (%)16 (12)7 (24)
 Positive sputum culture, n (%)20 (15)10 (35)
 Positive BAL culture, n (%)11 (8)13 (45)
  • BAL, bronchoalveolar lavage; ECOG, Eastern Cooperative Oncology Group.